First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential...
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of...
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.